Heart Failure Management Guidelines

Introduction to Heart Failure

The American College of Cardiology notes that HFrEF has robust evidence-based guideline-directed medical therapy (GDMT) proven to reduce mortality, while HFpEF management centers on SGLT2 inhibitors for prognostic benefit, diuretics for symptom relief, and aggressive comorbidity control 1, 2

The American College of Cardiology recommends initiating all four pillars of GDMT to achieve substantial mortality and hospitalization reduction, including ACE inhibitors/ARBs or preferably ARNIs, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors 3, 4
Beta-blockers reduce mortality by approximately 35% in HFrEF patients 3, 4
Mineralocorticoid receptor antagonists reduce mortality by 30% in HFrEF patients 3, 4
Device therapy, such as ICD and CRT, is recommended based on QRS duration and LVEF thresholds 3, 4

The European Heart Journal recommends SGLT2 inhibitors as the cornerstone of HFpEF management, with dapagliflozin and empagliflozin reducing composite endpoint of worsening HF and cardiovascular death by 18% and 21%, respectively 5, 2
Mineralocorticoid receptor antagonists have limited evidence in HFpEF, but may be considered in patients with LVEF 40-50% or persistent symptoms despite SGLT2 inhibitors 2, 6
Loop diuretics are recommended for congestion relief, with titration to lowest effective dose maintaining euvolemia 6, 2

The American College of Cardiology recommends achieving BP <130/80 mmHg in HFpEF patients, with prioritization of ACE inhibitors, ARBs, or ARNIs combined with diuretics 2
Hypertension treatment reduces incident HF risk by approximately 50% 3
Atrial fibrillation management involves controlling ventricular rate to 60-100 bpm using beta-blockers or non-dihydropyridine calcium channel blockers, and anticoagulation based on CHA₂DS₂-VASc score 2

The European Heart Journal recommends supervised exercise training programs for both HFpEF and HFrEF patients, with large, clinically meaningful improvements in exercise capacity and quality of life 5, 2
Dietary modifications, such as restricting sodium intake to <2-3 g/day, are recommended for both subtypes 2

The American College of Cardiology defines HFrEF as LVEF ≤40%, HFmrEF as LVEF 41-49%, and HFpEF as LVEF ≥50% 4, 8, 1
HFpEF diagnosis requires elevated natriuretic peptides and evidence of structural heart disease or diastolic dysfunction on echocardiography 1, 9, 2

The American College of Cardiology recommends monitoring for GDMT titration and optimization in HFrEF patients, and device interrogation if ICD/CRT is present 3, 4
HFpEF patients require regular checks of renal function and electrolytes, especially with MRAs, and monitoring of symptoms, vital signs, and daily weights at every visit 2

The European Heart Journal recommends cardiac rehabilitation programs, heart failure nurses, and early palliative care discussions for both HFpEF and HFrEF patients 2